ACME UNITED CORP — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Acme United reported Q2 2026 net sales of $62.7M (up 16% YoY from $54.0M), with net income of $5.1M or $1.22/diluted share (up 6% YoY). Organic sales (excluding My Medic acquisition on Jan 15, 2026) grew 8%. The My Medic acquisition contributed $8.7M in incremental sales but minimal earnings due to its seasonal Q4-weighted profitability model. Six-month net income declined 6% to $6.0M ($1.46/share) versus $6.4M ($1.57/share) YoY, pressured by Q1 results and tariff-related margin headwinds. On July 15, 2026, the company refinanced into a new $65M syndicated credit facility (HSBC, Royal Bank of Canada subsidiary) expiring July 15, 2029, replacing the prior $65M facility.
Why this rating
Mixed results: strong Q2 sales/earnings offset by H1 decline; My Medic is strategic but small (est. ~$14.5M net paid; <11% of market cap). Tariff drag, seasonal integration delays limit near-term impact. Routine refinancing. Moderate business development.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.